Dosage and Administration

Oral Administration
Usual Dosages for the Treatment of Infection
Mild to Moderate Infections - One 625 mg tablet twice a day or one
375mg table thrice a day
Severe Infections - One 625 mg tablet thrice a day
EXMOCLAV- 625 tablets is not recommended in children aged 12 years and below.
Tablets should be swallowed whole without chewing. If required, tablets may be broken in half and swallowed without chewing.

Indications
To reduce the development of drug resistant bacteria and maintain the effectiveness of amoxycillin/clavulanate potassium and other antibacterial drugs, amoxycillin/clavulanic acid should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
EXMOCLAV- 625 is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*
• Lower Respiratory Tract Infections caused by betalactamase-producing isolates of Haemophilusinfluenzae and Moraxella catarrhalis.
• Acute Bacterial Otitis Media caused by betalactamase-producing isolates of H. influenzae and M. catarrhalis.
• Sinusitis caused by betalactamase-producing isolates of H. influenzae and M. catarrhalis.
• Skin and Skin Structure Infections caused by betalactamase-producing isolates of Staphylococcus aureus, Escherichia coli, and Klebsiella species.
• Urinary Tract Infections caused by betalactamase-producing isolates of E. coli, Klebsiella species, and Enterobacter species.
• Bone and joint infections
• Other infections e.g.intra-abdominal sepsis and dental infections.

Contraindications
EXMOCLAV- 625 is contraindicated in patients with a history of serious hypersensitivity reactions (e.g. anaphylaxis or Stevens-Johnson syndrome) to amoxycillin, clavulanate or to other betalactam antibacterial drugs (e.g.penicillins and cephalosporins).
EXMOCLAV- 625is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with EXMOCLAV- 625
Mild to Moderate Infections One 625 mg tablet twice a day or one
375mg table thrice a day
Severe Infections One 625 mg tablet thrice a day